Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Blood (2024) 143 (20): 2053–2058.

https://doi.org/10.1182/blood.2023021184

Published: 2024

Includes: Supplemental data

Journal Articles

Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML

Blood (2023) 142 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2023-180141

Published: 2023

Journal Articles

Outcome of Infants Treated on Total Therapy for Infants with Acute Lymphoblastic Leukemia I: Results from a Non-Randomized Multi-Center Study

Blood (2023) 142 (Supplement 1): 823.

https://doi.org/10.1182/blood-2023-177798

Published: 2023

Journal Articles

Identifying Tumor-Specific Immune Response and Biomarkers of High-Risk Hodgkin Lymphoma Patients Treated with and without Brentuximab on Children's Oncology Group Trial AHOD1331

Keri Toner, Hema Dave, Gloria Pezzella, Qinglin Pei, Terzah M. Horton, Kara M. Kelly, Lisa Giulino Roth, Sharon M. Castellino, Catherine M. Bollard

Blood (2023) 142 (Supplement 1): 4383.

https://doi.org/10.1182/blood-2023-180791

Published: 2023

Journal Articles

Results from the Phase 1 Portion of a Trial of Oral Ixazomib Combined with Chemotherapy in Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoma in Children, Adolescents and Young Adults: A Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

Eric S. Schafer, Yueh-Yun Chi, Jemily Malvar, Teresa Rushing, Andrew Doan, Holly L. Pacenta, Reuven J. Schore, Richard Sposto, Roy Leong, Paul S. Gaynon, Jeffrey E. Rubnitz, Julio C. Barredo, Tamra Slone, Melinda Pauly, Alan S. Wayne, Deepa Bhojwani, Terzah M. Horton

Blood (2023) 142 (Supplement 1): 2872.

https://doi.org/10.1182/blood-2023-180414

Published: 2023

Journal Articles

Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

Blood (2022) 140 (Supplement 1): 6387–6389.

https://doi.org/10.1182/blood-2022-159694

Published: 2022

Journal Articles

A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease

Blood (2022) 140 (Supplement 1): 1722–1723.

https://doi.org/10.1182/blood-2022-165233

Published: 2022

Journal Articles

Targeting Vimentin (VIM) in Acute Myelogenous Leukemia (AML)

Stefan Hubner, Marina Konopleva, Zhihong Zeng, Fieke W Hoff, Yihua Qiu, Vivian Ruvolo, Terzah M. Horton, Steven M. Kornblau

Blood (2022) 140 (Supplement 1): 6260–6261.

https://doi.org/10.1182/blood-2022-163664

Published: 2022

Journal Articles

RPPA-Profiling in Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia Identifies Protein Patterns Associated with Outcome

Fieke W Hoff, Lourdes Sriraja, Yihua Qiu, Gaye Jenkins, Andrew Ligeralde, David T. Teachey, Brent L. Wood, Meenakshi Devidas, Mignon L. Loh, Todd A. Alonzo, Amina A Qutub, Evangelia Petsalaki, Steven M. Kornblau, Terzah M. Horton

Blood (2022) 140 (Supplement 1): 6352–6353.

https://doi.org/10.1182/blood-2022-163881

Published: 2022

Journal Articles

High Immunoproteasome Expression As Indicator for Sensitivity to Bortezomib-Containing Chemotherapy in Newly Diagnosed, Standard and Intermediate Risk, T-Cell Acute Lymphoblastic Leukemia Patients from Children's Oncology Group Trial AALL1231

Margot S.F. Roeten, Johan van Meerloo, Zinia Kwidama, Gaye Jenkins, Suzanne N. van Dijk, David T. Teachey, Meenakshi Devidas, Mignon L. Loh, Gertjan J.L. Kaspers, Sonja Zweegman, Gerrit Jansen, Jacqueline Cloos, Terzah M. Horton

Blood (2022) 140 (Supplement 1): 9183–9184.

https://doi.org/10.1182/blood-2022-162412

Published: 2022

Journal Articles

Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML

Blood (2022) 140 (Supplement 1): 159–161.

https://doi.org/10.1182/blood-2022-162842

Published: 2022

Journal Articles

A gene expression–based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma

Rebecca L. Johnston, Anja Mottok, Fong Chun Chan, Aixiang Jiang, Arjan Diepstra, Lydia Visser, Adèle Telenius, Randy D. Gascoyne, Debra L. Friedman, Cindy L. Schwartz, Kara M. Kelly, David W. Scott, Terzah M. Horton, Christian Steidl

Blood (2022) 139 (6): 889–893.

https://doi.org/10.1182/blood.2021011941

Published: 2022

Includes: Supplemental data

Journal Articles

Valosin-Containing Protein (VCP/p97) Is Prognostically Unfavorable in Subtypes of Acute Leukemia, and Negatively Correlates with UPR-Proteins IRE1 and GRP78

Fieke W Hoff, Yihua Qiu, Brandon Brown, Robert B. Gerbing, Alan S. Gamis, Richard Aplenc, Edward A. Kolb, Todd A. Alonzo, Soheil Meshinchi, Gaye Jenkins, Terzah M. Horton, Steven M. Kornblau

Blood (2021) 138 (Supplement 1): 3447.

https://doi.org/10.1182/blood-2021-147066

Published: 2021

Journal Articles

Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 3487.

https://doi.org/10.1182/blood-2021-151837

Published: 2021

Journal Articles

Molecular Evolution of Classical Hodgkin Lymphoma Revealed Though Whole Genome Sequencing of Hodgkin and Reed-Sternberg Cells

Blood (2021) 138 (Supplement 1): 805.

https://doi.org/10.1182/blood-2021-148663

Published: 2021

Journal Articles

Heat shock factor 1 (HSF1-pSer 326 ) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report

Fieke W. Hoff, Anneke D. van Dijk, Yihua Qiu, Peter P. Ruvolo, Robert B. Gerbing, Amanda R. Leonti, Gaye N. Jenkins, Alan S. Gamis, Richard Aplenc, E. Anders Kolb, Todd A. Alonzo, Soheil Meshinchi, Eveline S. J. M. de Bont, Sophia W. M. Bruggeman, Steven M. Kornblau, Terzah M. Horton

Blood (2021) 137 (8): 1050–1060.

https://doi.org/10.1182/blood.2020005208

Published: 2021

Includes: Supplemental data

Journal Articles

Proteomics in Pediatric Acute Myeloid and T-Cell Lymphoblastic Leukemia: Shared Individual Protein Expression Patterns Co-Cluster into Overall Distinct Combinations

Fieke W Hoff, BSc, Anneke D. van Dijk, MD, Yihua Qiu, Eveline S. de Bont, MD PhD, Steven M. Kornblau, MD, Terzah M Horton, MD PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-138522

Published: 2020

Journal Articles

Loss of H3K27 Methylation Identifies Poor Outcome in Adult-Onset Acute Myeloid Leukemia

Anneke D. van Dijk, MD, Fieke W Hoff, BSc, Yihua Qiu, Eveline S. de Bont, MD PhD, Sophia W.M. Bruggeman, PhD, Terzah M Horton, MD PhD, Steven M. Kornblau, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-139387

Published: 2020

Journal Articles

Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor

Natalia Baran, PhDMD, Alessia Lodi, PhD, Yogesh Dhungana, PhD, Shannon RENEE Sweeney, PhD, Pandey Renu, PhD, Shelley Herbrich, PhD, Fieke W Hoff, BSc, Anna Skwarska, PhD, Mecit Kaplan, MS, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, MSc, Marc Warmoes, PhD, Shanti Rojas-Sutterlin, PhD, Andre Haman, PhD, Diogo Troggian Veiga, PhD, Ken Furudate, DDM, PhD, Helen Ma, MS, Karine Harutyunyan, PhD, Wentao Yang, Mihai Gagea, MDPhD, Di Du, PhD, May Daher, Luciana Melo Garcia, MD, Sujan Piya, PhD, Vivian Ruvolo, MS, Sriram Shanmugavelandy, Ningping Feng, PhD, Jason P Gay, MS, Ondrej Havranek, MDPhD, Jared Henderson, MS, Katarzyna Tomczak, PhD, Marcin Kaminski, PhD, Daniel Herranz, PharmD, Adolfo Ferrando, MD, PhD, Elias Jabbour, MD, Maria E Di Francesco, PhD, David T. Teachey, MD, Terzah M. Horton, MD PhD, Katayoun Rezvani, MD PhD, Jun J. Yang, PhD, Steven M. Kornblau, MD, Eric Davis, MD, Koichi Takahashi, MD PhD, Michael Andreeff, MD PhD, Joseph R Marszalek, PhD, Philip Lorenzi, PhD, Jiyang Yu, PhD, Stefano Tiziani, PhD, Trang Hoang, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-136801

Published: 2020

Journal Articles

Increased Tumor Specific Cytotoxic T Cell Responses and Reversion to a Favorable Cytokine Profile after Treatment in Patients with Newly Diagnosed High Risk Hodgkin Lymphoma Treated on Children's Oncology Group Trial-AHOD1331

Hema Dave, Mimi Mai, Anushree Datar, Gaye Jenkins, BS, Qinglin Pei, PhD, Yue Wu, MS, Frank G. Keller, MD, Sharon M. Castellino, MD MSc, Terzah M Horton, MD PhD, Catherine M. Bollard, MD MBChB

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-136376

Published: 2020

NARROW

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML

Outcome of Infants Treated on Total Therapy for Infants with Acute Lymphoblastic Leukemia I: Results from a Non-Randomized Multi-Center Study

Identifying Tumor-Specific Immune Response and Biomarkers of High-Risk Hodgkin Lymphoma Patients Treated with and without Brentuximab on Children's Oncology Group Trial AHOD1331

Results from the Phase 1 Portion of a Trial of Oral Ixazomib Combined with Chemotherapy in Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoma in Children, Adolescents and Young Adults: A Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease

Targeting Vimentin (VIM) in Acute Myelogenous Leukemia (AML)

RPPA-Profiling in Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia Identifies Protein Patterns Associated with Outcome

High Immunoproteasome Expression As Indicator for Sensitivity to Bortezomib-Containing Chemotherapy in Newly Diagnosed, Standard and Intermediate Risk, T-Cell Acute Lymphoblastic Leukemia Patients from Children's Oncology Group Trial AALL1231

Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML

A gene expression–based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma

Valosin-Containing Protein (VCP/p97) Is Prognostically Unfavorable in Subtypes of Acute Leukemia, and Negatively Correlates with UPR-Proteins IRE1 and GRP78

Molecular Evolution of Classical Hodgkin Lymphoma Revealed Though Whole Genome Sequencing of Hodgkin and Reed-Sternberg Cells

Heat shock factor 1 (HSF1-pSer 326 ) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report

Proteomics in Pediatric Acute Myeloid and T-Cell Lymphoblastic Leukemia: Shared Individual Protein Expression Patterns Co-Cluster into Overall Distinct Combinations

Loss of H3K27 Methylation Identifies Poor Outcome in Adult-Onset Acute Myeloid Leukemia

Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor

Increased Tumor Specific Cytotoxic T Cell Responses and Reversion to a Favorable Cytokine Profile after Treatment in Patients with Newly Diagnosed High Risk Hodgkin Lymphoma Treated on Children's Oncology Group Trial-AHOD1331

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only